Recent Finacing
Recent Raise
Repare Therapeutics develops oncology drugs exploiting synthetic lethality and DNA damage‑repair vulnerabilities using its SNIPRx CRISPR-enabled platform combining target discovery, structural biology, computational biology, medicinal chemistry, and clinical informatics.
